SCHEMBL100765

SCHEMBL100765

c1coc(-c2ncco2)n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.46
LTA4H P09960 2/20 0.45
BRD4 O60885 2/20 0.38
CHRNA7 P36544 1/20 0.34
CHRNA10 Q9GZZ6 1/20 0.34
CHRNA9 Q9UGM1 1/20 0.34
PIN1 Q13526 1/20 0.34
GLRA3 O75311 1/20 0.33
GLRB P48167 1/20 0.33
HDAC4 P56524 1/20 0.33
ADRA1A P35348 4/20 0.32
ADRA1D P25100 3/20 0.32
ADRA2A P08913 2/20 0.32
ADRA1B P35368 1/20 0.32
KCNJ1 P48048 1/20 0.30
KCNH2 Q12809 1/20 0.30
ADORA2A P29274 1/20 0.30
ADORA1 P30542 1/20 0.30
CFTR P13569 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722557 0.82 LTA4H (0.64) HPGDSLTA4HBRD4CHRNA7CHRNA10
SCHEMBL5820538 0.80 NOTUM (0.43) HPGDS
SCHEMBL28257875 0.80 LTA4H (0.62) HPGDSLTA4HBRD4CHRNA7CHRNA10
SCHEMBL28362996 0.80 LTA4H (0.62) HPGDSLTA4HBRD4CHRNA7CHRNA10
SCHEMBL28320605 0.80 LTA4H (0.62) HPGDSLTA4HBRD4CHRNA7CHRNA10
SCHEMBL66901 0.80 HPGDS (0.48) HPGDSLTA4HBRD4CHRNA7CHRNA10
SCHEMBL5200683 0.78 HPGDS (0.35) HPGDSLTA4HBRD4
SCHEMBL6830738 0.78 CYP1A2 (0.40) HPGDSLTA4HBRD4CHRNA7CHRNA10
SCHEMBL9455041 0.78 HPGDS (0.35) HPGDSLTA4HBRD4
SCHEMBL1919495 0.78 HPGDS (0.52) HPGDSLTA4HBRD4PIN1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115583958-A Synthesis method of dihydrothia (oxa) zole [3',2':1,5] dihydroimidazole [4,5-b ] piperidine derivative 河南师范大学 2023-01-10 CN claimed
CN-115304606-A Degradation agent for simultaneously targeting BTK and GSPT1 proteins 清华大学 2022-11-08 CN claimed
US-20090181998-A1 OPIOID RECEPTOR SUBTYPE-SELECTIVE AGENTS UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2009-07-16 US claimed
CN-101309922-A Amino-aza-adamantane derivatives and methods of use ABBOTT LAB (US) 2008-11-19 CN claimed
WO-2008064317-A1 LIPOPHILIC OPIOID RECEPTOR ACTIVE COMPOUNDS UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2008-05-29 WO claimed
WO-2008064318-A2 PERIPHERAL OPIOID RECEPTOR ACTIVE COMPOUNDS UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2008-05-29 WO claimed
EP-1819721-A1 MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE Plant Bioscience Limited (GB) 2007-08-22 EP claimed
WO-2006124687-A1 OPIOID RECEPTOR SUBTYPE-SELECTIVE AGENTS UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2006-11-23 WO claimed
WO-2006054102-A1 MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE PLANT BIOSCIENCE LIMITED (GB) 2006-05-26 WO claimed
EP-4665862-A1 PYRUVATE SENSOR AND RELATED METHOD Abbott Diabetes Care Inc. (US) 2025-12-24 EP disclosed
EP-4648680-A2 BIOSENSORS WITH HYDROPHILIC POLYURETHANE MEMBRANES Abbott Diabetes Care Inc. (US) 2025-11-19 EP disclosed
US-20250281084-A1 COMPOSITION, COATING, AND METHOD FOR REDUCING EARLY/LATE SENSOR ATTENUATION OF ANALYTE BIOSENSOR ABBOTT DIABETES CARE INC. 2025-09-11 US disclosed
US-20250213152-A1 BACKGROUND INTERFERENCE MITIGATION FOR HIGH SENSITIVITY KETONE SENSING ABBOTT DIABETES CARE INC. (US) 2025-07-03 US disclosed
WO-2025137203-A1 GLUCOSE OXIDASE SENSORS WITH IMPROVED STABILITY ABBOTT DIABETES CARE, INC. (US) 2025-06-26 WO disclosed
WO-1995030703-A1 ENERGY POLYMERIZABLE COMPOSITIONS, HOMOPOLYMERS AND COPOLYMERS OF OXAZOLINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-11-16 WO disclosed
EP-0629624-A1 Tetrazole derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-12-21 EP disclosed
EP-0627406-A1 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1994-12-07 EP disclosed
EP-0605228-A1 Thiazolidinedione derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1994-07-06 EP disclosed
EP-0331554-A1 Composition, which permits to make compatible at least two incompatible thermoplastic polymers, its application for the fabrication of thermoplastic alloys and thermoplastic alloys obtained ELF ATOCHEM S.A. (FR) 1989-09-06 EP disclosed
US-4254049-A ANTIINFLAMMATORY AGENTS; USED TO INHIBIT JOINT DETERIORIATION OF ARTHRITIS AMERICAN CYANAMID COMPANY (US) 1981-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181998-A1 OPIOID RECEPTOR SUBTYPE-SELECTIVE AGENTS OPRM1, OPRK1, OPRL1 HPGDS 565/4885LTA4H 657/4885BRD4 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.